Corporate calendar for GRI Bio, Inc. (GRI): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2008-12-29 | $0.4890 | 108.07% |
Stock Splits
| Date | Ratio |
|---|---|
| 2026-01-26 | 1:28 |
| 2025-02-24 | 1:17 |
| 2024-06-18 | 1:13 |
| 2024-01-30 | 1:7 |
| 2023-04-24 | 1:30 |
Price
| Price | $1.81 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABP · BDRX · CANF · CLDI · CNSP · GNPX · INM
Explore sector: Healthcare · Biotechnology
More sections of GRI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks